{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:58:41Z","timestamp":1790801921682,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117061","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:08:57Z","timestamp":1790320137000},"page":"117061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-5390","authenticated-orcid":false,"given":"Chiara L.","family":"Blomen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kelpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"K\u00f6tt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-6661","authenticated-orcid":false,"given":"Mareike","family":"Rutenkr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-0880","authenticated-orcid":false,"given":"Isabelle","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-7137","authenticated-orcid":false,"given":"Stefan W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2026.117061_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117061_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2026.117061_bib3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC Melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study","volume":"42","author":"Luke","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2026.117061_bib4","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III\/IV Melanoma: 5-Year efficacy and biomarker results from checkmate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2026.117061_bib5","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/jnci\/djad081","article-title":"Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study","volume":"115","author":"Helgadottir","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.117061_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116201","article-title":"Five-year survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study","volume":"234","author":"Helgadottir","year":"2026","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.117061_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2026.117061_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2026.117061_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2024.100021","article-title":"Adjuvant systemic therapy in melanoma: relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?","volume":"2","author":"van Akkooi","year":"2024","journal-title":"EJC Skin Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.117061_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104295","article-title":"Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028","volume":"10","author":"Donia","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.117061_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113989","article-title":"Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy","volume":"202","author":"K\u00f6tt","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.117061_bib12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13046-025-03457-w","article-title":"In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition","volume":"44","author":"Heidrich","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2026.117061_bib13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-25-2274","article-title":"Circulating tumor DNA Is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanoma","volume":"32","author":"Ramelyte","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2026.117061_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1470-2045(25)00139-1","volume":"26","author":"Syeda","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.117061_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-026-01123-4","article-title":"Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization","volume":"23","author":"Johnson","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117061_bib16","first-page":"361","article-title":"Biomarkers in adjuvant and neoadjuvant treatment of melanoma","volume":"76","author":"K\u00f6tt","year":"2025","journal-title":"Dermatol (Heidelb)"},{"issue":"10","key":"10.1016\/j.ejca.2026.117061_bib17","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/pon.5446","article-title":"Advanced cancer patient preferences for receiving molecular profiling results","volume":"29","author":"Best","year":"2020","journal-title":"Psychooncology"},{"issue":"3","key":"10.1016\/j.ejca.2026.117061_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-017-4338-x","article-title":"Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?","volume":"165","author":"Partridge","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2026.117061_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-025-07797-1","article-title":"Patient perceptions around the use of clinico-pathologic and genomic tools in the management of early breast cancer","volume":"214","author":"Beltran-Bless","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2026.117061_bib20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2147\/CMAR.S235777","article-title":"Cancer patient-reported preferences and knowledge for liquid biopsies and blood biomarkers at a comprehensive cancer center","volume":"12","author":"Lee","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"4","key":"10.1016\/j.ejca.2026.117061_bib21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/oncolo\/oyac266","article-title":"Decision-making and health-related quality of life in patients with melanoma considering adjuvant immunotherapy","volume":"28","author":"Atkinson","year":"2023","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ejca.2026.117061_bib22","first-page":"21","article-title":"The control preferences scale","volume":"29","author":"Degner","year":"1997","journal-title":"Can J Nurs Res"},{"issue":"8","key":"10.1016\/j.ejca.2026.117061_bib23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/0284186X.2020.1762926","article-title":"Cancer patients' preferred and perceived level of involvement in treatment decision-making: an epidemiological study","volume":"59","author":"Hahlweg","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2026.117061_bib24","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1186\/1471-2458-13-948","article-title":"Measuring health literacy in populations: illuminating the design and development process of the European Health Literacy Survey Questionnaire (HLS-EU-Q)","volume":"13","author":"S\u00f8rensen","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ejca.2026.117061_bib25","series-title":"Erwachsenen in Deutschland","author":"Jordan","year":"2015"},{"issue":"3","key":"10.1016\/j.ejca.2026.117061_bib26","first-page":"274","article-title":"Fear of progression in breast cancer patients--validation of the short form of the Fear of Progression Questionnaire (FoP-Q-SF)]","volume":"52","author":"Mehnert","year":"2006","journal-title":"Z Psychosom Med Psychother"},{"issue":"10","key":"10.1016\/j.ejca.2026.117061_bib27","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.ejca.2026.117061_bib28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jamainternmed.2018.2317","article-title":"Effect of a patient and clinician communication-priming intervention on patient-reported goals-of-care discussions between patients with serious illness and clinicians: a randomized clinical trial","volume":"178","author":"Curtis","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.117061_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"issue":"4","key":"10.1016\/j.ejca.2026.117061_bib30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing--when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2026.117061_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102788","article-title":"Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma","volume":"129","author":"De Simoni","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.117061_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.pec.2023.107720","article-title":"Biomarker testing communication, familiarity, and informational needs among people living with breast, colorectal, and lung cancer","volume":"112","author":"Fortune","year":"2023","journal-title":"Patient Educ Couns"},{"issue":"3","key":"10.1016\/j.ejca.2026.117061_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6913","article-title":"Understanding communication between patients and healthcare professionals regarding comprehensive biomarker testing in precision oncology: a scoping review","volume":"13","author":"Pichler","year":"2024","journal-title":"Cancer Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:00:42Z","timestamp":1790798442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"alternative-id":["S0959804926008439"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117061","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117061"}}